Management of CLL

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 
DEFINITION & OVERVIEW
* Indolent B-cell malignancy — progressive accumulation of small, mature-appearing lymphocytes in peripheral blood, bone marrow, spleen, and lymph nodes
* All CLL cases contain clonal rearrangements of immunoglobulin heavy and light chain genes
* Primarily a GERIATRIC DISEASE — median age at diagnosis: 72 years
* Most common inherited leukemia — familial risk 2–4× higher with family history
* CURRENTLY INCURABLE — patients will universally relapse after primary treatment
* Survival ranges from 1 to 20 years; clinical course varies greatly
* Richter's transformation: CLL may transform into aggressive non-Hodgkin lymphoma (usually DLBCL) — occurs in 2–16% of patients; median survival 8–12 months

STAGING

Rai Staging:
* Stage 0: Lymphocytosis only [lowest risk] * Stage I: Lymphocytosis + lymphadenopathy
* Stage II: Lymphocytosis + hepatomegaly or splenomegaly
* Stage III: Lymphocytosis + anemia
* Stage IV: Lymphocytosis + thrombocytopenia [highest risk]

Binet Staging:
* Stage A: <3 lymphoid areas involved — early, often asymptomatic
* Stage B: >=3 lymphoid areas involved
* Stage C: anemia and/or thrombocytopenia

PROGNOSTIC FACTORS

Poor prognosis markers:
* Unmutated IGHV (<=2% mutated) — POOR prognosis; NOT a good prognostic factor (common exam trap: unmutated = poor; mutated = favorable)
* Del(17p) / TP53 mutation — "ultra-high risk"; resistant to chemoimmunotherapy
* Del(11q) — poor prognosis
* ZAP-70 >=20% expression — poor prognosis; surrogate for unmutated IGHV (ZAP-70 flow cytometry lacks standardization; not recommended outside clinical trials)
* CD38 >=30% expression — poor prognosis; surrogate for unmutated IGHV
* CD49D >=30% expression — poor prognosis; STRONGEST single predictor of OS and treatment-free survival among flow cytometry markers
* HIGH β-2-microglobulin — poor prognosis
* High WBC/ALC, advanced age, high LDH

Favorable prognosis markers:
* Mutated IGHV (>2%) — FAVORABLE prognosis; potential for durable remission with FCR
* Del(13q14) as SOLE abnormality — BEST prognosis and longest median survival among all cytogenetic changes (NOT an adverse feature — common exam trap)
* LOW β-2-microglobulin — favorable

Prognostic marker summary:
Biomarker                      Favorable                       Unfavorable (poor)
IGHV mutation             Mutated (>2%)             Unmutated (<=2%)
ZAP-70                            <20%                               >=20%
CD38                                <30%                               >=30%
CD49D                             <30%                               >=30%
Beta-2-microglobulin    Low                                 Elevated/High
Cytogenetics                    Del(13q14) sole             Del(17p), Del(11q), complex

CLL-IPI incorporates: age, clinical stage, β-2 microglobulin, IGHV mutation status, TP53 status

INDICATIONS FOR TREATMENT

* WATCH AND WAIT is the standard for asymptomatic early-stage disease (Rai stage 0, Binet stage A) — no survival benefit from early treatment
* Asymptomatic Rai stage 0 OR Binet stage A → observation only, regardless of age or comorbidities
* Treatment deferred until clinical indications develop

Treatment indicated when ANY of the following are present:
* Progressive marrow failure → worsening anemia or thrombocytopenia
* Massive or symptomatic lymphadenopathy/splenomegaly
* Lymphocyte doubling time <6 months OR >=50% increase in ALC over 2 months
* Disease-related symptoms: weight loss, extreme fatigue, fevers without infection

FIRST-LINE TREATMENT

Patients WITHOUT del(17p) or TP53 mutation:

Regimen Notes

• Acalabrutinib ± obinutuzumab Category 1 preferred; continuous therapy (ELEVATE-TN): Best for patients wanting LONG-TERM continuous treatment, Preferred if patient has CKD or is age >=65
• Zanubrutinib Category 1 preferred; continuous therapy: Fewer cardiac effects than ibrutinib (AF rate 2.5% vs 10.1%), Preferred BTKi in patients with pre-existing AF
• Venetoclax + obinutuzumab Category 1 preferred; fixed-duration ~1 year: Best for patients wanting TIME-LIMITED therapy, Also preferred in patients with cardiac comorbidities
• Ibrutinib Moved to "other recommended" due to cardiac toxicities (AF up to 16%, bleeding); avoid in pre-existing AF
• FCR (fludarabine + cyclophos- ONLY for young (<65-70), fit, mutated IGHV patients phamide + rituximab) No CKD, no del(17p)/del(11q), no significant comorbidities, Potential for durable long-term remission
• CLL10 trial: FCR superior to BR in fit patients <65 yrs: Adding rituximab (FC → FCR) improves OS and PFS
• Chlorambucil + obinutuzumab Elderly/unfit patients only
• BR (bendamustine + rituximab) Alternative CIT for older or less fit

Patients WITH del(17p) or TP53 mutation — "ultra-high risk":
* Preferred: acalabrutinib ± obinutuzumab, zanubrutinib, venetoclax + obinutuzumab
* Other options: ibrutinib, high-dose methylprednisolone + rituximab, alemtuzumab
* Alemtuzumab + rituximab: recommended specifically for del(17p) symptomatic patients
* Chemoimmunotherapy generally avoided — very poor response in del(17p)/TP53 (chlorambucil = very low response rates; median survival <3 years with standard chemo)

Key first-line rules — HIGH YIELD:
* FCR eligibility requires: age <65-70, fit, no CKD (CrCl = primary predictor of fludarabine toxicity), mutated IGHV, no del(11q)/del(17p)
* Young, fit, mutated IGHV, no comorbidities → FCR for durable remission
* Patient wanting fixed-duration therapy → venetoclax + obinutuzumab (~1 year)
* Patient with atrial fibrillation → AVOID ibrutinib; prefer venetoclax or acalabrutinib; zanubrutinib is preferred BTKi if BTKi required (AF rate 2.5% vs ibrutinib 10.1%)
* Ofatumumab: NO longer recommended for CLL (common distractor)
* Alemtuzumab: ONLY for del(17p) in first-line; NOT recommended without del(17p)
* Del(13q14) = favorable; alemtuzumab NOT indicated for del(13q) patients
* Ibrutinib moved to "other recommended" — newer BTKi (acalabrutinib, zanubrutinib) now preferred due to better cardiac safety profile

RELAPSED/REFRACTORY (R/R) CLL

Preferred R/R regimens:
* Acalabrutinib, zanubrutinib (continuous)
* Venetoclax + rituximab — Category 1; MURANO trial (superior PFS and OS vs BR); fixed-duration 2 years in R/R setting; preferred in patients with AF or cardiac comorbidities
* Venetoclax retreatment may be considered after long remission from first course
* Patient with AF or cardiac history → venetoclax + rituximab preferred over ibrutinib

Post-BTK and BCL-2 inhibitor failure:
* Pirtobrutinib — non-covalent BTK inhibitor; overcomes resistance to prior covalent BTKi (ibrutinib, acalabrutinib, zanubrutinib)
* PI3K inhibitors: idelalisib + rituximab (Category 2B), duvelisib
* CAR-T (anti-CD19): investigational in refractory CLL

Key R/R rules:
* Repeat FCR in relapse = NOT preferred — more effective novel therapies available
* Bendamustine + rituximab + idelalisib = NOT recommended — toxicity concerns (Category 2B)
* Chlorambucil + obinutuzumab = NOT recommended in second-line
* Del(11q) patients respond well to initial FCR but require novel agents at relapse

DRUG-SPECIFIC TOXICITIES & KEY POINTS

BTK Inhibitors — continuous therapy until progression or toxicity:

Ibrutinib:
* Most common toxicity: minor bleeding up to 66% of patients (mechanism: inhibits platelet signaling and adhesion on von Willebrand factor)
* Serious bleeding: ~9%; highest risk in first 3–6 months
* Patient counseling: avoid vitamin E, fish oils, flaxseed, NSAIDs
* Hold 3 days before/after minor surgery; 7 days before/after major surgery
* Atrial fibrillation in up to 16% of patients — AVOID in pre-existing AF
* Hypertension develops/worsens in >75% over 30 months (NOT hypotension)
* TLS = NOT associated with ibrutinib (TLS = venetoclax)
* Periorbital edema = NOT ibrutinib (periorbital edema = imatinib in CML)

Acalabrutinib:
* Most common toxicity: HEADACHE up to 40% of patients (typically early onset, resolves in 4–8 weeks)
* Manage headache with: hydration, caffeine, acetaminophen/NSAIDs
* Hypertension ~3% (NOT hypotension)
* NOT associated with TLS or periorbital edema
* TLS = venetoclax; periorbital edema = imatinib

Zanubrutinib:
* Similar to ibrutinib but FEWER cardiac effects
* AF rate: 2.5% vs ibrutinib 10.1% — preferred BTKi in patients with pre-existing AF

Pirtobrutinib:
* Non-covalent BTK inhibitor — overcomes resistance to prior covalent BTKi
* Used post-ibrutinib/acalabrutinib/zanubrutinib failure

Key BTKi rules:
* Both ibrutinib AND idelalisib cause TREATMENT-INDUCED LYMPHOCYTOSIS (redistribution lymphocytosis) — does NOT signify disease progression; continue therapy
* FALSE to say idelalisib does NOT cause lymphocytosis — it DOES (same as ibrutinib)
* Combining ibrutinib or idelalisib with rituximab blunts but does NOT eliminate lymphocytosis
* All BTKi cause hypertension, NOT hypotension

Venetoclax (BCL-2 inhibitor):
* Major toxicity: TUMOR LYSIS SYNDROME (TLS) — potentially fatal
* TLS prophylaxis is REQUIRED for all patients starting venetoclax
* 5-week ramp-up: 20 → 50 → 100 → 200 → 400 mg daily
* TLS prophylaxis: oral hydration (1.5–2 L) + allopurinol started 2–3 days BEFORE first dose
* TLS labs: K+, Mg2+, phosphate, creatinine, uric acid, LDH
* NOT associated with: pancreatitis, lower extremity edema, or visual changes (pancreatitis = nilotinib/ponatinib in CML; edema = imatinib)

Venetoclax TLS risk stratification & monitoring:

Risk Criteria Monitoring (20 & 50 mg doses)
Low/Med No node >=5 cm AND ALC <25x10^9/L Outpatient: pre-dose, 6-8h, 24h Then: outpatient pre-dose only
HIGH Any node >=10 cm INPATIENT: pre-dose, 4, 8, 12, 24h OR (ALC >=25x10^9/L AND any node >=5 cm) Then: outpatient pre-dose, 6-8h, 24h

Example: ALC = 30x10^9/L (>=25) AND node = 7 cm (>=5 cm) → HIGH risk
→ inpatient monitoring at 20 mg and 50 mg doses
→ outpatient pre-dose, 6-8h, and 24h for subsequent dose escalations

Idelalisib (PI3K inhibitor):
* Key toxicity: SEVERE DIARRHEA/COLITIS (~10% grade >=3; median onset 9.5 months) — manage with steroids (budesonide or systemic corticosteroids)
* Black box warnings: hepatotoxicity, severe diarrhea/colitis, pneumonitis, intestinal perforation
* Available through REMS program
* Also causes treatment-induced lymphocytosis (same as ibrutinib)
* NOT associated with: pancreatitis, lower extremity edema, visual changes
* NOT combined with bendamustine — toxicity concerns

SUPPORTIVE CARE & INFECTION PROPHYLAXIS

Indication Agent Notes

PJP prophylaxis Sulfamethoxazole- Continue until CD4 >200/uL (purine analogs, bendamustine, trimethoprim Dapsone if sulfa allergy
idelalisib, duvelisib, alemtuzumab) (SMX-TMP). NOTE: PJP prophylaxis NOT required for acalabrutinib or zanubrutinib

Herpes/VZV prophylaxis Acyclovir During treatment and after (purine analogs, idelalisib, alemtuzumab)

Zoster prophylaxis Zoster vaccine Shingrix (NOT live vaccine), (BTKi, treatment-naive CLL) recombinant, Recommended for BTKi patients
adjuvanted and treatment-naive CLL (Shingrix)

CMV reactivation Ganciclovir/ ONLY if CMV viremia confirmed valganciclovir NOT routine prophylaxis

IVIG IVIG ONLY if IgG <500 mg/dL AND recurrent sinopulmonary infections (>=2 in 6 months requiring IV antibiotics), NOT routine

* Live vaccines (e.g., Zostavax): STRICTLY AVOIDED in ALL CLL patients (immunocompromised)
* Shingrix (recombinant) is the ONLY acceptable zoster vaccine in CLL

COMPLICATIONS

Richter's Transformation (RT):
* Transformation to aggressive lymphoma (usually DLBCL) — occurs in 2–16% of patients
* Prognosis: median survival 8–12 months
* Clinical features: RAPID-ONSET (days to weeks) bulky lymphadenopathy, fevers, splenomegaly, weight loss — typically within first 1–2 years of BTKi treatment
* Ibrutinib/zanubrutinib RESISTANCE onset = INSIDIOUS (not rapid) — key distinction
* Redistribution lymphocytosis = EARLY treatment effect (peaks week 2, resolves by week 12) — would NOT occur after 18 months of BTKi therapy
* Rapid lymphadenopathy + fever + weight loss after months of BTKi → think RT first

Autoimmune complications:
* AIHA (autoimmune hemolytic anemia): 10–25% lifetime risk — most common autoimmune cytopenia in CLL
* ITP (immune thrombocytopenic purpura): 2–5% risk

ITP treatment ladder:
* First-line: Corticosteroids (prednisone/dexamethasone)
* Second-line: IVIG (when rapid platelet rise needed); rituximab
* Third-line: Cyclosporine; thrombopoietin agents (romiplostim, eltrombopag, avatrombopag); fostamatinib

Causes of anemia in CLL — ALL of the following contribute:
* Autoimmune hemolytic anemia (AIHA) — most common cause
* Red blood cell aplasia (PRCA) — ~1% of CLL patients
* Bone marrow infiltration by CLL cells → progressive marrow failure
* Marrow suppression from alkylating agents (e.g., cyclophosphamide in FCR)
* Hypersplenism — enlarged spleen sequesters and destroys RBCs
* GI blood loss — especially from ibrutinib-associated bleeding (up to 66% of patients)

Infections:
* Leading cause of morbidity in CLL
* Due to hypogammaglobulinemia + treatment-induced immunosuppression

HIGH-YIELD PEARLS — MUST MEMORIZE

1. CLL is INCURABLE — all patients eventually relapse; watch and wait for Rai 0/Binet A asymptomatic (no survival benefit from early treatment)
2. del(13q) sole abnormality = BEST prognosis; del(17p)/TP53 = WORST (ultra-high risk) — del(13q) is a FAVORABLE feature, NOT adverse
3. ZAP-70 >=20%, CD38 >=30%, CD49D >=30% = poor prognosis surrogates for unmutated IGHV CD49D is the STRONGEST single predictor of OS and treatment-free survival
4. Unmutated IGHV = POOR; Mutated IGHV = FAVORABLE (not the other way around)
5. Low β-2-microglobulin = favorable; HIGH = poor
6. FCR = only for young (<65-70), fit, mutated IGHV, no del(17p)/del(11q), no CKD CrCl = primary predictor of fludarabine toxicity — CKD excludes FCR
7. Patient wanting time-limited therapy → venetoclax + obinutuzumab (~1 year, 1st line)
8. Ibrutinib + AF = avoid; zanubrutinib preferred BTKi in AF (AF rate 2.5% vs 10.1%) Venetoclax preferred in patients with significant cardiac comorbidities
9. Alemtuzumab in first-line = ONLY for del(17p) patients; NOT without del(17p)
10. Ofatumumab = NO longer recommended for CLL
11. Venetoclax = TLS risk; BTK inhibitors = bleeding/cardiac risk (NOT TLS)
12. Acalabrutinib most common toxicity = HEADACHE (up to 40%); ibrutinib most common toxicity = MINOR BLEEDING (up to 66%)
13. Periorbital edema = imatinib (CML); pancreatitis = nilotinib/ponatinib — NOT venetoclax; NOT idelalisib; NOT BTKi
14. Both ibrutinib AND idelalisib cause redistribution lymphocytosis — does NOT signify progression; FALSE to say idelalisib does NOT cause it
15. Idelalisib = severe diarrhea/colitis (10% grade >=3); manage with steroids; REMS program; NOT combined with bendamustine
16. Rapid lymphadenopathy + constitutional symptoms after BTKi = Richter's transformation Redistribution lymphocytosis = early treatment effect; NOT present after 18 months
17. PJP prophylaxis (SMX-TMP): required for purine analogs, idelalisib, duvelisib, alemtuzumab, bendamustine — NOT required for BTKi alone
18. Acyclovir: herpes prophylaxis for idelalisib and alemtuzumab patients
19. Shingrix (recombinant) = recommended for BTKi patients; Zostavax (live) = STRICTLY AVOIDED
20. IVIG: only if IgG <500 mg/dL + recurrent infections — NOT routine. Ganciclovir: only if CMV viremia confirmed — NOT routine prophylaxis
21. ITP first-line = corticosteroids; second-line = IVIG or rituximab; third-line = cyclosporine, TPO agents
22. Venetoclax TLS HIGH risk = inpatient monitoring at 20 & 50 mg doses. HIGH risk = any node >=10 cm OR (ALC >=25x10^9/L AND any node >=5 cm) Subsequent doses in high risk = outpatient pre-dose, 6-8h, 24h
23. Repeat FCR at relapse = NOT preferred; bendamustine + rituximab + idelalisib = NOT recommended (toxicity); chlorambucil + obinutuzumab = NOT second-line
24. Hypertension (NOT hypotension) is associated with all BTKi

A. JF is a retired 68-year-old male with a history of chronic kidney disease, hypertension, and hypercholesterolemia. He was in his usual state of health until approximately 6 months ago, when he noted significant and painful lymph node swelling in his neck and groin. His family medical doctor prescribed an antibiotic, but his symptoms did not resolve. He returned to his family doctor, where his CBC revealed marked lymphocytosis (lymphocytes = 27,000 B cells/mm³). Flow cytometry confirmed the diagnosis of CLL. After further workup, JF is diagnosed with Binet stage B disease. His cytogenetic analysis reveals that he has a del(13q) mutation and unmutated IGHV. He is considered medically fit to receive treatment, and he is interested in receiving a regimen that can be completed in a short amount of time. 

Given this information, which of the following treatment regimens is the most appropriate first-line therapy for JF?

• A. Acalabrutinib
• B. Chlorambucil + ofatumumab
• C. Fludarabine, cyclophosphamide and rituximab (FCR)
• D. Venetoclax + obinutuzumab

[expand] The most appropriate first-line therapy for JF is D. Venetoclax + obinutuzumab.

Clinical Reasoning

• Time-Limited Therapy: JF specifically requested a regimen that can be completed in a short amount of time. While BTK inhibitors like acalabrutinib (Option A) are preferred first-line options, they must be taken continuously until disease progression. In contrast, venetoclax + obinutuzumab is a fixed-duration regimen that is completed in approximately one year.
• Comorbidities and Age: JF is over 65 and has CKD, so he is ineligible for fludarabine-based chemoimmunotherapy regimens such as FCR (Option C). This is because creatinine clearance is a primary predictor of fludarabine toxicity.
• Efficacy and Prognosis: JF has unmutated IGHV, which is associated with a poor prognosis. Venetoclax + obinutuzumab is a Category 1 preferred regimen that has demonstrated superior progression-free survival (PFS) in patients with unmutated IGHV and other high-risk markers.
• Status of Other Options: Treatment with ofatumumab (Option B) is no longer recommended for the first-line treatment of CLL.

Summary of Response

Although acalabrutinib is a Category 1 preferred regimen, its requirement for continuous administration does not align with JF's request for a time-limited treatment. Because JF is ineligible for FCR due to his age and renal function, venetoclax + obinutuzumab is the only Category 1 preferred choice that meets his clinical needs and personal preference for a 12-month treatment duration.

[/expand]

B. JF will be receiving venetoclax + obinutuzumab for his newly diagnosed CLL.

Which of the following statements about venetoclax is correct?

• A. Pancreatitis is common.
• B. Tumor lysis syndrome prophylaxis is required.
• C. Lower extremity edema often occurs.
• D. Visual changes are frequent.

[expand] The correct statement about venetoclax is B. Tumor lysis syndrome prophylaxis is required.

Rationale

• Mandatory TLS Mitigation: Tumor lysis syndrome (TLS) is a potentially deadly adverse effect of venetoclax due to its high potency and rapid induction of tumor cell death.
• Stepwise Ramp-Up: To minimize this risk, venetoclax dosing must follow a five-week stepwise "ramp-up" schedule, starting at 20 mg daily and increasing to the target dose of 400 mg daily.
• Required Prophylaxis: All patients starting venetoclax must receive prophylaxis, which typically includes oral hydration (1.5–2 L) and a xanthine oxidase inhibitor such as allopurinol initiated 2–3 days prior to the first dose.
• Patient-Specific Risk: For JF, who has an absolute lymphocyte count (ALC) of 27,000 cells/mm³, he is categorized as at least medium risk for TLS. This requires outpatient monitoring of blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) and consideration of additional intravenous hydration.

Evaluation of Other Options

• A. Pancreatitis: This is not a common side effect of venetoclax. The sources identify pancreatitis as a unique toxicity associated with certain tyrosine kinase inhibitors (TKIs) used in CML, specifically nilotinib and ponatinib.
• C. Lower Extremity Edema: This is not frequently associated with venetoclax. Edema is more commonly seen with imatinib (periorbital edema) or moxetumomab pasudotox-tdfk.
• D. Visual Changes: The sources explicitly state that visual disturbances are not frequent or common adverse effects of venetoclax.

[/expand]

A. JF is a retired 68-year-old male with a history of chronic kidney disease, hypertension and hypercholesterolemia. He was in his usual state of health until approximately 6 months ago, when he noted significant and painful lymph node swelling in his neck and groin. His family medical doctor prescribed an antibiotic, but his symptoms did not resolve. He returned to his family doctor, where his CBC revealed marked lymphocytosis (lymphocytes = 27,000 B cells/mm3). Flow cytometry confirmed the diagnosis of CLL. After further workup, JF is diagnosed with Binet stage B disease. His cytogenetic analysis reveals that he has a del(13q) mutation and unmutated IGHV. He is considered medically fit to receive treatment.

Which of the following treatment regimens is the most appropriate first-line therapy for JF?

• A. Acalabrutinib +/- obinutuzumab
• B. Chlorambucil + ofatumumab
• C. Fludarabine, cyclophosphamide and rituximab (FCR)
• D. Alemtuzumab + rituximab

[expand] The most appropriate first-line therapy for JF is A. Acalabrutinib +/- obinutuzumab.

Rationale:  According to the provided patient case continuation and clinical guidelines:

• Ineligibility for Chemoimmunotherapy (FCR): Although JF is considered "medically fit," he is 68 years old and has chronic kidney disease. The sources explicitly state that creatinine clearance is the primary predictor of toxicity for fludarabine-based regimens. Being over 65 and having renal impairment makes him ineligible for FCR in the first-line setting.
• Preferred Status of Acalabrutinib: For patients aged 65 or older, or those with significant comorbidities, acalabrutinib +/- obinutuzumab is a Category 1 preferred regimen. This recommendation is based on the ELEVATE-TN trial, which demonstrated significantly longer progression-free survival (PFS) with acalabrutinib-containing arms compared to chlorambucil + obinutuzumab.
• Poor Prognostic Markers: JF has unmutated IGHV, which is associated with a more aggressive disease course and poorer outcomes. Targeted therapies like acalabrutinib have shown consistent benefit in PFS across high-risk subgroups, including those with unmutated IGHV.
• Exclusion of Other Options:
  • Ofatumumab (Option B): Treatment with ofatumumab is no longer recommended for the treatment of CLL in the first-line setting.
  • Alemtuzumab (Option D): This agent is not recommended for the first-line treatment of patients who do not have the del(17p) mutation. JF has a del(13q) mutation.

[/expand]

B. JF has now been receiving ibrutinib for 18 months. Over the past two weeks, he has noted rapidly enlarging cervical, axillary, and inguinal lymphadenopathy. He also reports new fevers, splenomegaly, and unintentional weight loss. Which of the following is the most likely cause of JF’s new complaints?

• A. Richter’s transformation
• B. Ibrutinib resistance
• C. Redistribution lymphocytosis
• D. Tuberculosis infection

[expand] The most likely cause of JF’s new complaints is A. Richter’s transformation.

Reasoning: According to the provided patient case scenarios and disease information, the diagnosis is based on the following:

• Rapid and Severe Onset: Rapid onset (over just two weeks), nature, and severity of symptoms—specifically rapidly growing lymphadenopathy, new fevers, splenomegaly, and unintentional weight loss—are hallmark signs of a transformation to a more aggressive malignancy.
• Definition of Richter’s Transformation (RT): RT is the transformation of CLL into an aggressive non-Hodgkin lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). It is typically suspected when a patient with known CLL develops these specific constitutional symptoms and asymmetrical lymph node growth.
• Timing on Therapy: JF has been on ibrutinib for 18 months. The sources note that Richter’s transformation typically occurs within the first 1–2 years of treatment.

Why the Other Options are Less Likely

• Ibrutinib Resistance (Option B): While resistance to ibrutinib can occur, its onset is typically insidious rather than the rapid, explosive growth seen in this case.
• Redistribution Lymphocytosis (Option C): This is a transient phenomenon where CLL cells move from the lymph nodes into the blood, causing a rise in lymphocyte count. However, it occurs early in the treatment course (peaking at week 2 and usually resolving by week 12) and would not occur after 18 months of therapy.
• Tuberculosis Infection (Option D): Tuberculosis infection is not associated with ibrutinib therapy.

[/expand]

A. DG is a 63-year-old male with CLL with del(11q). His past medical history is significant for hypothyroidism, well-controlled atrial fibrillation, and gastroesophageal reflux disease. He received treatment with FCR three years ago and achieved a complete response. After experiencing a recurrence of painful cervical lymphadenopathy, he has recently been diagnosed with relapsed CLL. Which of the following regimens is most appropriate for DG at this point in his course?

• A. Repeat FCR
• B. Chlorambucil + ofatumumab
• C. Zanubrutinib
• D. Bendamustine, rituximab + idelalisib

[expand] The most appropriate regimen for DG at this point in his course is C. Zanubrutinib.

Reasoning

1. Status of Treatment Options:

   • Zanubrutinib is a Category 1 recommendation for use in the second-line setting. It has a superior overall response rates and improved progression-free survival (PFS) compared to ibrutinib in patients with relapsed or refractory CLL.
   • Repeat FCR (Option A) is not the most appropriate choice because more effective novel therapies are now available for second-line treatment.
   • Chlorambucil + ofatumumab (Option B) is incorrect because ofatumumab is no longer recommended for the treatment of CLL.
   • Bendamustine, rituximab + idelalisib (Option D) is not recommended by guidelines due to concerns regarding toxicity.

2. Impact of Comorbidities: DG has a history of atrial fibrillation. Zanubrutinib was associated with a statistically significantly lower rate of atrial fibrillation (2.5%) compared to ibrutinib (10.1%). This makes zanubrutinib a particularly appropriate Bruton’s tyrosine kinase inhibitor (BTKi) for a patient with pre-existing cardiac rhythm issues.

3. Genetics and Prior Response: DG has the del(11q) mutation. While patients with this mutation respond well to initial treatment with fludarabine-based regimens (like the FCR he received three years ago), novel agents like BTK inhibitors are preferred in the relapsed setting to manage the aggressive nature of the disease associated with this mutation.

[/expand]

B. DG has now been receiving zanubrutinib for 18 months. Over the past two weeks, he has noted rapidly enlarging cervical, axillary, and inguinal lymphadenopathy. He also reports new fevers, splenomegaly, and unintentional weight loss. Which of the following is the most likely cause of DG’s new complaints?

• A. Richter’s transformation
• B. Zanubrutinib delayed hypersensitivity reaction
• C. Redistribution lymphocytosis
• D. Tuberculosis infection

[expand] Correct answer = A (Richter’s transformation).

The rapid onset, nature, and severity of DG’s symptoms suggest a transformation to a more aggressive malignancy, commonly known as histologic transformation or Richter’s transformation (RT). There are no documented reports of BTKi delayed hypersensitivity reactions. Redistribution lymphocytosis occurs early in a patient’s treatment course and would not occur after 18 months of therapy. Tuberculosis infection is not associated with zanubrutinib.

[/expand]

DG is a 63-year old male with CLL with del(11q). His past medical history is significant for hypothyroidism, well-controlled atrial fibrillation, and gastroesophageal reflux disease. He received treatment with FCR three years ago and achieved a complete response. After experiencing a recurrence of painful cervical lymphadenopathy, he has recently been diagnosed with relapsed CLL. Which of the following regimens is most appropriate for DG at this point in his course?

• A. Repeat FCR
• B. Chlorambucil + obinutuzumab
• C. Venetoclax + rituximab
• D. Bendamustine, rituximab + idelalisib

[expand] The most appropriate regimen for DG at this point in his course is C. Venetoclax + rituximab.

Reasoning 

1. Category 1 Recommendation: This regimen is an NCCN Guidelines® Category 1 recommendation for the second-line treatment of relapsed or refractory CLL. Its preferred status is based on the results of the MURANO study, which demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to bendamustine + rituximab.
2. Addressing Atrial Fibrillation: DG has a history of atrial fibrillation. While other novel agents like ibrutinib (a BTK inhibitor) are also Category 1 recommendations, ibrutinib is well-documented to be associated with an increased risk of atrial fibrillation (occurring in up to 16% of patients). The sources note that venetoclax-based therapy may be preferred in patients with significant cardiac comorbidities to avoid these potential toxicities.
3. High-Risk Genetics: DG has the del(11q) mutation. The sources indicate that while these patients initially respond well to fludarabine-based regimens (like the FCR he received), they often experience rapid disease progression. The benefits of the venetoclax + rituximab regimen have been shown to be maintained across all biologic subgroups, including high-risk patients.

Evaluation of Other Options

• A. Repeat FCR: This is not appropriate because more effective novel therapies are now available for second-line treatment, and repeating chemoimmunotherapy is generally less effective in the relapsed setting.
• B. Chlorambucil + obinutuzumab: This is a first-line therapy option and is not currently recommended for the treatment of relapsed CLL.
• D. Bendamustine, rituximab + idelalisib: This combination is currently listed as a Category 2B recommendation and is not considered the most appropriate choice due to toxicity concerns.

[/expand]

A. DG is a 63-year old male with CLL with del(11q). His past medical history is significant for hypothyroidism, well-controlled atrial fibrillation and gastroesophageal reflux disease. He received treatment with FCR three years ago and achieved a complete response. He did not receive lenalidomide maintenance and has been followed by observation. After experiencing a recurrence of painful cervical lymphadenopathy, he has recently been diagnosed with relapsed CLL. Which of the following regimens is most appropriate for DG at this point in his course?

• A. Repeat FCR
• B. Ibrutinib
• C. Venetoclax + rituximab
• D. Bendamustine, rituximab + idelalisib

[expand] The most appropriate regimen for DG at this point in his course is C. Venetoclax + rituximab.

Rationale

1. Venetoclax + rituximab is a Category 1 preferred recommendation for the second-line treatment of relapsed or refractory CLL. This status is based on the MURANO study, which demonstrated superior progression-free survival (PFS) and overall survival compared to bendamustine + rituximab.
2. Managing Cardiac Comorbidities: While ibrutinib (Option B) is also a Category 1 recommendation, it is well-documented to increase the risk of atrial fibrillation, occurring in up to 16% of patients. Because DG has a history of atrial fibrillation, the sources suggest that venetoclax-based therapy may be preferred to avoid exacerbating his cardiac co-morbidities.
3. High-Risk Genetics (del(11q)): DG has the del(11q) mutation, which is associated with rapid disease progression and shorter survival when treated with conventional chemotherapy. While patients with this mutation respond well to initial FCR, novel agents like venetoclax have shown benefits that are maintained across all biological subgroups, including those with high-risk markers.

Evaluation of Other Options

• A. Repeat FCR: This is not the most appropriate choice because more effective novel therapies are now available for second-line treatment, and repeating chemoimmunotherapy is generally less effective in the relapsed setting.
• B. Ibrutinib: Although a Category 1 choice, it was moved to an "other recommended regimen"  specifically due to concerns regarding cardiac toxicities.
• D. Bendamustine, rituximab + idelalisib: This combination is currently a Category 2B recommendation and is not considered the most appropriate choice due to toxicity concerns.

[/expand]

B. DG is a 63-year-old male with relapsed CLL. He is not a candidate for ibrutinib, and thus he was planning to start venetoclax + rituximab. However, he cannot afford venetoclax + rituximab, so he will initiate idelalisib + rituximab instead. Which of the following statements about idelalisib is correct?

• A. Pancreatitis is common.
• B. Diarrhea may be severe.
• C. Lower extremity edema often occurs.
• D. Visual changes are frequent.

[expand] Based on the sources, the correct statement about idelalisib is B. Diarrhea may be severe.

Rationale: According to the clinical information and the specific patient case scenario provided:

• Severe Immune-Mediated Toxicity: Idelalisib is associated with significant immune-mediated adverse effects, most notably severe diarrhea or colitis.
• Frequency and Timing: Diarrhea is common and typically follows two peaks: a lower-grade diarrhea early in therapy (affecting ~30% of patients) and a severe diarrhea/colitis that occurs in approximately 10% of patients with a median onset of 9.5 months.
• Management: Because this toxicity is immune-mediated, colitis from idelalisib must be managed promptly with steroids, such as budesonide or systemic corticosteroids.
• Supportive Case Data: The sources explicitly identify Option B as the correct answer for DG’s specific scenario, clarifying that the other listed conditions are not common adverse effects of this agent.

Evaluation of Other Options

• A. Pancreatitis: This is not a common adverse effect of idelalisib. Pancreatitis is more commonly associated with certain tyrosine kinase inhibitors used for CML, such as nilotinib and ponatinib.
• C. Lower extremity edema: This is not frequently associated with idelalisib. Edema is a hallmark side effect of other agents like imatinib (periorbital edema) or moxetumomab pasudotox-tdfk.
• D. Visual changes: The sources explicitly state that visual changes are not common adverse effects for idelalisib.

[/expand]

C. DG is a 63-year old male who is receiving idelalisib + rituximab for the treatment of relapsed CLL. He has no known drug allergies. What supportive care measures should DG receive to prevent complications from his underlying disease and/or treatment regimens?

• A. Sulfamethoxazole-trimethoprim
• B. Zostavax
• C. Ganciclovir
• D. IVIG

[expand] The correct supportive care measure for DG is A. Sulfamethoxazole-trimethoprim.

Rationale: According to the provided clinical guidelines and specific case information for DG:

• PJP Prophylaxis Requirement: The sources explicitly state that Pneumocystis jiroveci pneumonia (PJP) prophylaxis with sulfamethoxazole-trimethoprim (or an equivalent) is recommended for all patients receiving idelalisib.
• Case Specificity: Because DG is receiving idelalisib as part of his relapsed CLL treatment, initiating this antibiotic is the standard of care to prevent a potentially life-threatening opportunistic infection.
• Duration: Prophylaxis for PJP is generally recommended to continue until the CD4+ T-cell count is greater than 200 cells/μL.

Evaluation of Other Options

• B. Zostavax: This is a live vaccine and should be strictly avoided in patients with CLL. The recombinant, adjuvanted zoster vaccine (Shingrix) is preferred for CLL patients instead.
• C. Ganciclovir: Prophylactic use of ganciclovir or valganciclovir is not warranted for DG unless he had confirmed CMV viremia present at the initiation of his therapy.
• D. IVIG: Intravenous immunoglobulin therapy is only appropriate if DG had recurrent sinopulmonary infections (defined as ≥2 in 6 months requiring IV antibiotics) and a documented serum IgG level < 500 mg/dL.

[/expand]

D-DG is a 63-year old male who is receiving idelalisib + rituximab for the treatment of relapsed CLL. What supportive care measures should DG receive to prevent complications from his underlying disease and/or treatment regimens?

• A. Acyclovir
• B. Zostavax
• C. Ganciclovir
• D. IVIG

[expand] Based on the sources, the correct supportive care measure for DG, who is receiving idelalisib, is A. Acyclovir.

Rationale: The sources explicitly state that patients receiving certain CLL therapies, including idelalisib, are at increased risk for viral infections:

• Herpes Prophylaxis: For the prevention of herpes virus infections, the sources recommend that patients receiving idelalisib should receive acyclovir or an equivalent during treatment and for a period thereafter.
• PI3K Inhibitor Specificity: Because idelalisib is a PI3K inhibitor, clinical guidelines list "VZV [Varicella-zoster virus] prophylaxis" as a necessary consideration for opportunistic infection management.

Evaluation of Other Options

• B. Zostavax: This is a live vaccine and the sources state it should be strictly avoided in all CLL patients. Live vaccines can be dangerous for immunocompromised patients, and Shingrix (a recombinant vaccine) is the preferred alternative for shingles prevention in this population.
• C. Ganciclovir: While idelalisib can lead to cytomegalovirus (CMV) reactivation, the sources clarify that prophylactic ganciclovir is not warranted unless the patient has confirmed CMV viremia at the start of therapy. The standard approach for most patients is regular monitoring via PCR.
• D. IVIG: Intravenous immunoglobulin therapy is not a routine supportive measure. It is only indicated if DG has documented serum IgG levels < 500 mg/dL and a history of recurrent sinopulmonary infections (defined as $\ge$ 2 in 6 months) requiring hospitalization or IV antibiotics.

[/expand]

A. MB is a 71-year-old female with newly diagnosed CLL who will be initiating therapy with acalabrutinib. Which of the following adverse effects are frequently seen with acalabrutinib and should be discussed during your counseling session with MB?

• A. Hypotension
• B. Tumor lysis syndrome
• C. Headache
• D. Periorbital edema

[expand] The adverse effect frequently seen with acalabrutinib that should be discussed with MB is C. Headache.

Rationale

• Commonality: Headache is the most commonly reported adverse effect of acalabrutinib, occurring in up to 40% of patients.
• Timing and Duration: This side effect typically occurs early in the treatment course and usually resolves spontaneously within 4 to 8 weeks.
• Management Strategies: Counseling for MB should include mitigation strategies such as hydration, caffeine supplementation, and the use of analgesics like acetaminophen.

Why the Other Options are Incorrect

• Hypotension (A): While acalabrutinib is associated with hypertension (occurring in approximately 3% of patients), hypotension has not been reported as a side effect of this medication.
• Tumor Lysis Syndrome (B): This potentially fatal complication is specifically associated with the initiation of venetoclax, not acalabrutinib.
• Periorbital Edema (D): This is a unique toxicity characteristic of imatinib therapy used in CML, but it is not commonly seen with acalabrutinib.

[/expand]

B. MB is a 71-year-old female with newly diagnosed CLL. She has no known drug allergies and will be initiating therapy with acalabrutinib.
What supportive care measure should MB receive to prevent complications from her underlying disease and/or treatment regimen?

• A. Zoster vaccine recombinant, adjuvanted
• B. Dapsone
• C. Valganciclovir
• D. IVIG

[expand] The correct supportive care measure for MB is A. Zoster vaccine recombinant, adjuvanted.

Rationale: According to the clinical guidelines for patients with Chronic Lymphocytic Leukemia (CLL):

• Vaccination Standard: The recombinant, adjuvanted zoster vaccine (Shingrix) is specifically recommended for patients who are treatment-naïve or for those being treated with a BTK inhibitor, such as MB who is starting acalabrutinib.
• Avoiding Live Vaccines: Conversely, the sources emphasize that all live vaccines (such as Zostavax®) must be strictly avoided in patients with CLL due to their immunocompromised state.

Why Other Options Are Incorrect

• Dapsone (Option B): This agent is typically used for PJP prophylaxis in patients with a sulfa allergy. However, the sources state that PJP prophylaxis is recommended for patients receiving purine analogs, PI3K inhibitors, or alemtuzumab—not for those on acalabrutinib.
• Valganciclovir (Option C): This is used for cytomegalovirus (CMV) prophylaxis, but only if CMV viremia is confirmed prior to therapy. There is no indication of CMV viremia for MB in the case description.
• IVIG (Option D): Intravenous immunoglobulin therapy is not routine. It is only indicated if the patient has documented serum IgG levels < 500 mg/dL and a history of recurrent sinopulmonary infections (defined as $\ge$ 2 in 6 months) requiring hospitalization or IV antibiotics.

[/expand]

A. FB is a 71-year-old male diagnosed with Binet stage B disease. His cytogenetic analysis reveals that he has a del(13q) mutation and unmutated IGHV. He is considered medically fit to receive treatment. Which of the following treatment regimens is the most appropriate first-line therapy for FB?

A. Ibrutinib
B. Chlorambucil and ofatumumab
C. Fludarabine, cyclophosphamide and rituximab (FCR)
D. Alemtuzumab and rituximab

[expand] The most appropriate first-line therapy for FB among the given choices is A. Ibrutinib.

Reasoning

1. Age and Eligibility for Chemoimmunotherapy (FCR): FB is 71 years old. The sources explicitly state that while fludarabine-based regimens like FCR (Option C) are preferred for younger, fit patients (typically < 65 years) with mutated IGHV, the benefit of improved progression-free survival (PFS) with FCR was not seen in patients > 65 years of age. Furthermore, creatinine clearance is a major predictor of fludarabine toxicity, often making patients in this age group ineligible for the regimen regardless of their perceived fitness.
2. Ibrutinib as a Standard of Care: For patients age $\ge$ 65 years without the del(17p) or TP53 mutation, ibrutinib is a Category 1 recommendation. It has demonstrated statistically significant improvements in PFS and overall survival (OS) compared to traditional chemoimmunotherapy (such as chlorambucil) in older untreated patients through trials like RESONATE-2.
3. Prognostic Markers (Unmutated IGHV): FB has unmutated IGHV, which is a marker for a more aggressive disease course and shorter survival with conventional chemotherapy. Novel agents like ibrutinib have shown consistent benefit in PFS across high-risk subgroups, including those with unmutated IGHV.
4. Exclusion of Other Options:
   • Chlorambucil and ofatumumab (Option B): The sources state that treatment with ofatumumab is no longer recommended for the treatment of CLL in the first-line setting.
   • Alemtuzumab and rituximab (Option D): Alemtuzumab is not recommended in the first-line setting for patients who do not have the del(17p) mutation. FB has a del(13q) mutation, which is generally associated with a favorable prognosis when seen as a sole abnormality.

Conclusion

Because FB is over 65 and has unmutated IGHV, FCR is inappropriate and less effective. Among the provided options, ibrutinib is the only standard, Category 1-recommended treatment that addresses his clinical profile.

[/expand]

B. FB is a 71-year old male with CLL who has been receiving ibrutinib for the past 18 months. Over the past two weeks, he has noted rapidly enlarging cervical, axillary and inguinal lymphadenopathy. He also reports new fevers, splenomegaly and unintentional weight loss. Which of the following is the most likely the cause of FB’s new complaints?

• A. Richter’s transformation
• B. Ibrutinib resistance
• C. Redistribution lymphocytosis
• D. Tuberculosis infection

[expand] Correct answer = A (Richter’s transformation).

The rapid onset, nature and severity of FB’s symptoms suggests a transformation to a more aggressive malignancy, commonly known as histologic transformation or Richter’s transformation (RT). While ibrutinib resistance does occur, the onset is often insidious. Redistribution lymphocytosis occurs early in a patient’s treatment course and would not occur after 18 months of therapy. Tuberculosis infection is not associated with ibrutinib.

[/expand]

C-FB is a 71-year old male with newly diagnosed CLL who will be initiating therapy with ibrutinib. Which of the following adverse effects are frequently seen with ibrutinib and should be discussed during your counseling session with FB?

• A. Hypotension
• B. Tumor lysis syndrome
• C. Minor bleeding
• D. Periorbital edema

[expand] The adverse effect frequently seen with ibrutinib that should be discussed during FB’s counseling session is C. Minor bleeding.

Rationale

According to the clinical information and toxicity profiles provided for ibrutinib:

• High Frequency: Minor bleeding is an extremely common side effect of ibrutinib, reported in up to 66% of patients.
• Mechanism: Ibrutinib is postulated to selectively inhibit platelet signaling and strongly affect platelet adhesion on von Willebrand factor.
• Timing: The risk of bleeding is highest during the first 3 to 6 months of treatment and typically decreases with continued therapy.
• Counseling Points: Patients starting ibrutinib should be advised to avoid certain supplements and medications that can further increase bleeding risk, such as vitamin E, fish oils, flaxseed, and NSAIDs.

Evaluation of Other Options

• A. Hypotension: This is incorrect. Ibrutinib is actually associated with hypertension (high blood pressure), which develops or worsens in over 75% of patients over a median of 30 months.
• B. Tumor Lysis Syndrome (TLS): This is incorrect. While TLS can occur in CLL patients with high tumor burdens, it is a hallmark risk specifically associated with the initiation of venetoclax or bendamustine-based therapy, rather than BTK inhibitors like ibrutinib.
• D. Periorbital Edema: This is incorrect. Periorbital edema (swelling around the eyes) is a unique toxicity characteristic of imatinib therapy used in CML, but it is not a frequent side effect of ibrutinib.

[/expand]

A 75-year-old man presents with a recently diagnosed asymptomatic CLL Rai stage 0. Which option is recommended?

A. Alemtuzumab (2%)
B. Chlorambucil (3%)
C. Fludarabine (2%)
D. Observation only - no therapy (93%)

[expand] For a 75-year-old man with asymptomatic, Rai stage 0 CLL, the recommended option is D. Observation only - no therapy (93%).

Rationale

According to clinical guidelines provided in the sources:

• Active Surveillance Standard: An "active surveillance" or "watch and wait" approach is the standard of care for asymptomatic patients with early-stage, low-risk disease, specifically defined as Rai stage 0 or Binet stage A.
• No Survival Benefit for Early Treatment: Multiple Phase III studies and meta-analyses have demonstrated that there is no statistically significant difference in survival between patients who receive early treatment for asymptomatic early-stage CLL and those whose treatment is deferred until a clinical indication arises.
• Indications for Treatment: In CLL, the decision to initiate therapy is based on the development of symptoms or disease progression, rather than the diagnosis itself. Treatment is typically deferred until the patient develops indications such as:
  • Disease-related constitutional symptoms (e.g., severe fatigue, unintended weight loss, fevers).
  • Progressive bone marrow failure (worsening anemia or thrombocytopenia).
  • Massive or symptomatic splenomegaly/lymphadenopathy.
  • Rapidly increasing lymphocyte counts (e.g., doubling time < 6 months).

Because this patient is currently asymptomatic and in the earliest clinical stage (Rai 0), starting any of the medical therapies listed (alemtuzumab, chlorambucil, or fludarabine) would offer no proven survival benefit and would subject the patient to unnecessary toxicities.

[/expand]

BR is a 62-year-old male who presents with fever and night sweats and is subsequently diagnosed with CLL His cytogenetic analysis reveals a del(17P) mutation. BR is physically active and has no comorbidity. Which of the following is the most appropriate for BR at this time?

• Alemtuzumab + Rituximab (45%)
• Chlorambucil (6%)
• Idelalisib + Rituximab (40%)
• Observation only - no treatment (9%)

[expand]For BR, the most appropriate option at this time is Alemtuzumab + Rituximab.

Reasoning

1. Indication for Treatment: Although CLL is often indolent, BR presents with disease-related constitutional symptoms, specifically fever and drenching night sweats. The sources establish that these symptoms are clear indications to initiate therapy rather than continuing with "active surveillance" or observation.
2. High-Risk Cytogenetics (del(17p)): BR has the del(17p) mutation, which is the single most important prognostic factor in CLL. This mutation involves the loss of the TP53 tumor suppressor gene, resulting in "ultra-high risk" disease that responds poorly to standard chemotherapy.
3. Treatment Selection for del(17p):
   • Alemtuzumab + Rituximab: The sources explicitly list alemtuzumab +/- rituximab as a recommended first-line treatment option specifically for patients with the del(17p)/TP53 mutation.
   • Chlorambucil (Option B): Standard chemoimmunotherapy like chlorambucil is associated with very low response rates and short median survival (less than 3 years) in patients with the del(17p) mutation and is generally not recommended.
   • Idelalisib + Rituximab (Option C): While idelalisib is effective for del(17p) in the relapsed or refractory setting, the clinical treatment tables in the sources categorize it as a second-line or subsequent therapy for these high-risk patients, rather than a primary first-line choice.
   • Observation (Option D): As noted, this is inappropriate because the patient is currently symptomatic.

Summary

Because BR is symptomatic and has the ultra-high-risk del(17p) mutation, he requires immediate treatment with a non-chemotherapy-based regimen. Among the provided choices, Alemtuzumab + Rituximab is the only one listed in the guidelines as an appropriate first-line option for this specific genetic profile.

[/expand]

KR is a 52-year-old patient who presents with complaints of fever, chills, and night sweats. Physical examination revealed cervical and axillary lymphadenopathy. He also had positive splenomegaly. He had a WBC of 63000, Hgb of 98 g/dL, Hct of 30%, and Platelets of 165000. WBC flow cytometry revealed a diagnosis of chronic lymphocytic leukemia (CLL) with poor cytogenetics. Which of the following is the best treatment option for KR?

• A Watch and wait (2%)
• B Pentostatin / Rituximab (1%)
• C Bendamustine (4%)
• D Fludarabine/Cyclophosphamide/Rituximab (92%)

[expand]For KR, the best treatment option among the choices provided is D. Fludarabine/Cyclophosphamide/Rituximab (FCR).

Rationale

1. Indication for Treatment: KR is symptomatic, presenting with constitutional symptoms (fever, chills, and night sweats), which are definitive indications to initiate therapy in CLL. His physical exam further reveals massive lymphadenopathy and splenomegaly, both of which represent progressive bulky disease requiring intervention.
2. Patient Fitness and Age: At 52 years old, KR is classified as a younger, physiologically fit "go-go" patient (typically defined as age < 65 years without significant comorbidities).
3. Cytogenetics and FCR:
   • KR is described as having "poor cytogenetics." In the context of younger CLL patients, unfavorable cytogenetics such as del(11q) have historically responded well to the combination of fludarabine and an alkylating agent (the components of FCR).
   • The CLL10 study demonstrated that in younger, physically fit patients, the FCR regimen produced significantly improved progression-free survival (PFS) compared to other chemoimmunotherapy regimens like bendamustine + rituximab (Option C).
   • While modern guidelines increasingly prioritize targeted small-molecule inhibitors (like BTK inhibitors), FCR remains a preferred and standard chemoimmunotherapy choice for young, fit patients in many clinical contexts and board-style assessments.

Evaluation of Other Options

• A. Watch and Wait: This is inappropriate because KR is symptomatic with constitutional symptoms and bulky disease; active surveillance is only for asymptomatic early-stage disease.
• B. Pentostatin / Rituximab: While purine analogues like pentostatin can be used in CLL, they are not the standard-of-care first-line choice for fit CLL patients in the same way FCR is. Pentostatin is more commonly a primary treatment for Hairy Cell Leukemia (HCL).
• C. Bendamustine: The CLL10 study explicitly showed that FCR was superior to bendamustine + rituximab regarding PFS in fit patients under age 65.

[/expand]

Which of the following statements is FALSE concerning idelalisib?

• A. Idelalisib is only available through the REMS program. (20%)
• B. It has a black box warning for hepatotoxicity, severe diarrhea/colitis, pneumonitis, and intestinal perforation. (9%)
• C. Unlike ibrutinib, idelalisib does not lead to a treatment-induced lymphocytosis. (57%)
• D. Idelalisib should be used with rituximab in patients with relapsed CLL who cannot tolerate aggressive chemotherapy. (19%)

[expand] The statement that is FALSE concerning idelalisib is C. Unlike ibrutinib, idelalisib does not lead to a treatment-induced lymphocytosis.

Rationale

• Redistribution Lymphocytosis is Universal for Kinase Inhibitors: The sources explicitly state that "redistribution lymphocytosis"—a transient increase in absolute lymphocyte count (ALC) caused by CLL cells moving from lymph nodes into the peripheral blood—can occur with all of the kinase inhibitors used to treat CLL.
• Evidence from Study 116: In the pivotal trial for idelalisib (Study 116), isolated lymphocytosis was observed, typically peaking at week 2 and resolving by week 12. While the addition of rituximab to idelalisib blunted and shortened the duration of this effect, it did not eliminate it.
• Clinical Significance: This phenomenon does not signify disease progression, and the sources emphasize that therapy should be continued when it occurs.

Verification of Other Statements

• Statement B (True): The sources confirm that idelalisib is associated with significant immune-mediated adverse effects, specifically highlighting hepatotoxicity (elevated liver function tests), severe diarrhea/colitis, and pneumonitis. (Note: While intestinal perforation is a known complication of severe colitis, the sources explicitly focus on the first three as primary concerns requiring steroid management).
• Statement D (True): FDA approval for idelalisib + rituximab was based on Study 116, which specifically enrolled patients with relapsed CLL who were unable to receive cytotoxic chemotherapy due to co-existing illnesses.
• Statement A (True/Distractor): While the provided snippets do not explicitly mention a REMS (Risk Evaluation and Mitigation Strategy) program for idelalisib, statement C is directly and scientifically contradicted by the detailed section in the sources regarding redistribution lymphocytosis occurring with all CLL kinase inhibitors.

[/expand]

FR is a 59-year-old female who is started on a fludarabine-based combination chemotherapy regimen for Rai stage IV chronic lymphocytic leukemia (CLL). Concurrent with this regimen, which of the following supportive care medications should be initiated?

• A. Sulfamethoxazole/trimethoprim (88%)
• B. Amoxicillin/clavulanate (1%)
• C. Leucovorin (3%)
• D. Pyridoxine (7%)

[expand] For FR, who is starting a fludarabine-based chemotherapy regimen, the correct supportive care medication to initiate is A. Sulfamethoxazole/trimethoprim.

Reasoning

• Fludarabine as a Purine Analog: Fludarabine belongs to the class of medications known as purine analogs,,.
• Increased Risk of Infection: Patients with CLL are more susceptible to infections than the general population due to both their underlying disease and the immunosuppressive properties of chemotherapy treatments like fludarabine,,.
• Mandatory PJP Prophylaxis: The sources explicitly state that Pneumocystis jiroveci pneumonia (PJP) prophylaxis with sulfamethoxazole-trimethoprim or an equivalent is recommended for all patients receiving purine analogs,,,.
• Duration of Prophylaxis: For patients on purine analogs, guidelines recommend considering the continuation of this prophylaxis until the patient's CD4 count is greater than 200 cells/mcL,,,.

Evaluation of Other Options

• B. Amoxicillin/clavulanate: While antibacterial prophylaxis can be useful for some CLL patients who cannot tolerate or do not qualify for IVIG, it is not the specific standard of care for preventing the opportunistic PJP infections associated with purine analogs,,.
• C & D. Leucovorin and Pyridoxine: The provided sources do not mention leucovorin or pyridoxine as recommended supportive care measures for patients undergoing fludarabine-based chemotherapy for CLL.

[/expand]

KT is a 56-year-old female who presents with a newly diagnosed Rai stage 3 CLL Further workup shows IGHV mutations and del13q mutation. Which of the following statements is TRUE?

• A. PT has several good prognostic factors: young age, unmutated immunoglobulin heavy-chain variable (IGHV), and del(13q) (20%)
• B. KT should be started on ibrutinib and needs to be counseled on the common side effects of thrombocytopenia, diarrhea, and bruising (26%)
• C. Rituximab should not be added to KT's regimen since it has not been shown to improve response rates. PFS or OS (2%)
• D. Since KT is young and does not have comorbidities, she should be started on chemoimmunotherapy (52%)

[expand] The true statement regarding KT’s clinical scenario is D. Since KT is young and does not have comorbidities, she should be started on chemoimmunotherapy.

Reasoning

1. Patient Profile and Indications for Treatment: KT is 56 years old (classified as a young, physiologically fit "go-go" patient) and presents with Rai stage 3 disease. The sources establish that advanced-stage CLL (Rai stages 3 or 4) is a definitive indication to initiate therapy.

2. The Significance of Mutated IGHV: KT has IGHV mutations, which is a highly favorable prognostic marker. The sources explicitly state that "FCR [fludarabine, cyclophosphamide, and rituximab] is still a recommended regimen and preferred for first-line therapy in young, fit patients with mutated IGHV". This preference exists because patients with mutated IGHV who receive chemoimmunotherapy can achieve durable, long-term remissions that may not require continuous therapy.

3. Favorable Cytogenetics: KT also has the del(13q) mutation. The sources note that del(13q), when it is the sole abnormality, is associated with a favorable prognosis and the longest median survival.

Why the Other Statements are False

• Statement A: This statement incorrectly identifies unmutated IGHV as a good prognostic factor. The sources clarify that unmutated IGHV (typically $\le$ 2% mutated) is actually associated with a poor prognosis and significantly decreased survival.
• Statement B: While ibrutinib is a Category 1 recommendation for first-line treatment, it is generally administered continuously until disease progression. For a young patient with mutated IGHV, the fixed-duration chemoimmunotherapy regimen (FCR) is often preferred to provide a long treatment-free interval.
• Statement C: This statement is incorrect because the addition of rituximab to chemo regimens (like the transition from FC to FCR) demonstrated improved overall survival and progression-free survival in younger, fit patients.

[/expand]

29. Adverse prognostic features in chronic lymphocytic leukemia are, except:

•   a. ZAP-70
•   b. CD38
•   c. Unmutated immunoglobulin Vh genes
•   d. del 13q14

[expand] The correct answer is d. del 13q14.

• ZAP-70: Expression of ZAP-70 in $\ge$ 20% of B lymphocytes is an unfavorable (adverse) prognostic factor associated with shorter progression-free survival (PFS) and overall survival (OS).
• CD38: Expression of CD38 in $\ge$ 30% of B lymphocytes is an unfavorable (adverse) prognostic factor associated with shorter PFS and OS.
• Unmutated immunoglobulin Vh genes (IGHV): Unmutated IGHV status (defined as $\le$ 2% mutated) is associated with a poor (adverse) prognosis and significantly decreased survival compared to cases with mutated IGHV.
• del 13q14: Deletion 13q (del(13q)), when it occurs as the sole cytogenetic abnormality, is associated with a favorable prognosis and the longest median survival among CLL patients.

[/expand]

The cause of anemia in CLL is:

1.   Gastrointestinal blood loss
2.   Hypersplenism
3.   Marrow suppression secondary to the use of alkylating agents
4.   Hemolytic anemia
5.   Red blood cell aplasia
6.   All of the above

[expand] Based on the clinical guidelines and disease information provided in the sources, the cause of anemia in Chronic Lymphocytic Leukemia (CLL) can be attributed to f. All of the above. While not all of these causes are primary manifestations of the disease biology itself, they are all documented complications arising from the progression of CLL or its standard treatments:

• Hemolytic anemia (AIHA): The sources state that Autoimmune hemolytic anemia (AIHA) is the most common form of autoimmune cytopenia in CLL. It occurs when non-malignant B cells produce antibodies directed against red blood cell antigens.
• Red blood cell aplasia (PRCA): Pure red cell aplasia is a known autoimmune complication that occurs in approximately 1% of patients with CLL. It is a condition where the bone marrow stops producing red blood cells.
• Marrow suppression (Infiltration and Treatment):
  • Disease Progression: Anemia is a hallmark of "progressive bone marrow failure" as CLL cells infiltrate and crowd out healthy hematopoiesis.
  • Alkylating Agents: Common chemoimmunotherapy regimens, such as FCR (which includes the alkylating agent cyclophosphamide), are associated with significant myelosuppression and hematologic toxicities.
• Hypersplenism: CLL is frequently associated with massive or symptomatic splenomegaly. An enlarged spleen often leads to hypersplenism, where the organ prematurely sequesters and destroys red blood cells, contributing to anemia.
• Gastrointestinal blood loss: While not a direct symptom of CLL, the sources highlight that minor and serious bleeding events are extremely common side effects of targeted therapies like ibrutinib (reported in up to 66% of patients). Significant bleeding in the gastrointestinal tract can lead to iron-deficiency anemia.

[/expand]

Which of the following biomarkers is associated with poor prognosis in CLL?

• A. Low β-2 -micro globulins
• B. ZAP70 
• C. CD49D 
• D. mutated IGHV

[expand] Based on the sources, both B. ZAP70 and C. CD49D are biomarkers associated with a poor prognosis in CLL. However, the sources highlight a specific distinction regarding their predictive strength.

Prognostic Biomarkers for Poor Prognosis

According to the clinical data and the outcome association tables provided:

• CD49D (Option C): Expression of CD49d in $\ge$ 30% of B lymphocytes is associated with aggressive disease biology, progressive disease, and lymphadenopathy. Notably, the sources state that among flow cytometry markers (CD38, CD49d, and ZAP-70), CD49d appears to be the strongest predictor of overall survival and treatment-free survival.
• ZAP70 (Option B): Expression of ZAP-70 in $\ge$ 20% of B lymphocytes is also an unfavorable prognostic factor associated with shorter progression-free survival and overall survival. However, the sources note that ZAP-70 flow cytometry lacks standardization and its evaluation is generally not recommended outside of clinical trials.

Biomarkers Associated with Favorable Prognosis

The other options listed are associated with better clinical outcomes:

• Low β-2 -micro globulins: While elevated levels of Low β-2 -microglobulins are a strong independent indicator of poor survival and shorter treatment-free intervals, low levels are categorized as a favorable prognostic factor.
• Mutated IGHV (Option D): IGHV mutation status is a key predictor of survival. Mutated IGHV (defined as > 2% mutated) is associated with a favorable prognosis, whereas unmutated IGHV ($\le$ 2% mutated) is associated with a poor prognosis and significantly decreased survival.

Summary Table

[/expand]

KL is a 70 years old patient his medical history is significant for Uncontrolled DM, asthma & MI, 2 days ago he was diagnosed  with CLL Binet Stage A what type of treatment he should  receive?  

• A. Acalabrutinib +/- obinutuzumab  
• D. Alemtuzumab + rituximab  
• B. Zanubrutinib  
• D. No treatment, only surveillance

[expand] The most appropriate course of action for KL is D. No treatment, only surveillance.

Reasoning

1. Staging and Risk Level: KL has been diagnosed with Binet Stage A CLL. The sources categorize this as early-stage, low-risk disease.

2. Standard of Care (Active Surveillance): For patients with Binet Stage A (or Rai Stage 0) who are asymptomatic, the standard approach is "active surveillance" (also known as "watch and wait").

3. No Survival Benefit for Early Treatment: Multiple Phase III studies and meta-analyses have demonstrated that there is no statistically significant difference in survival between patients treated immediately upon diagnosis of early-stage CLL and those whose treatment is deferred until a clinical indication arises.

4. Lack of Indications for Treatment: Treatment in CLL is initiated based on clinical evidence of disease progression or symptoms, such as:

   • Disease-related constitutional symptoms (e.g., severe fatigue, night sweats, fevers).
   • Massive or symptomatic lymphadenopathy/splenomegaly.
   • Progressive bone marrow failure (worsening anemia or thrombocytopenia).
   • Rapidly increasing lymphocyte counts (doubling time < 6 months).

   Since KL was diagnosed only two days ago and is in Binet Stage A without any mentioned symptoms or complications from CLL, starting medical therapy (Options A, B, or D) would offer no proven benefit and would expose him to unnecessary toxicities.

Impact of Comorbidities

While KL has significant medical history (MI, asthma, uncontrolled DM), these do not change the initial recommendation for surveillance in Stage A CLL. However, if KL's disease were to progress to the point of requiring therapy in the future:

• His history of MI would make him a poor candidate for ibrutinib due to its documented cardiac toxicities, specifically the risk of atrial fibrillation and other cardiac events.
• In that future scenario, agents with lower cardiac risk profiles, such as acalabrutinib or zanubrutinib, would be preferred if a BTK inhibitor were chosen.

[/expand]

FJ is a 55-year-old patient who was diagnosed with CLL 3 weeks ago. He started ibrutinib, but unfortunately, after 12 months he relapsed and is planned to start second-line Venetoclax + Rituximab. His ALC = 30 x 10^9/L, largest lymph node measures about 7 cm, serum K = 3.5 meq/L, Mg = 1.8 mmol/L, and CrCL = 60 ml/min. What monitoring plan should he undergo?

• A. Outpatient: Pre-dose, 6-8 hours and 24 hours at first dose of 20 mg and 50 mg, then Pre-dose before subsequent doses  
• B. Outpatient: Pre-dose, 4, 8, 12, and 24 hours at first dose of 20 mg and 50 mg, then pre-dose before subsequent doses  
• C. Inpatient: Pre-dose, 4, 8, 12, and 24 hours at first dose of 20 mg and 50 mg, then Outpatient: Pre-dose before subsequent doses  
• D. Inpatient: Pre-dose, 4, 8, 12, and 24 hours at first dose of 20 mg and 50 mg, then Outpatient: Pre-dose, 6-8 hours and 24 hours at subsequent doses  

[expand] Based on the clinical parameters provided for FJ, the correct monitoring plan is D. Inpatient: Pre-dose, 4, 8, 12 and 24 hours at first dose of 20 mg and 50 mg, then Outpatient: Pre-dose, 6-8 hours and 24 hours at subsequent doses.

Rationale

1. Determining Tumor Burden Category: To establish the appropriate prophylaxis and monitoring for the venetoclax "ramp-up" phase, FJ must be categorized as Low, Medium, or High tumor burden.

   • FJ’s absolute lymphocyte count (ALC) is 30 x 10⁹/L (which meets the $\ge$ 25 x 10⁹/L threshold).
   • FJ’s largest lymph node measures 7 cm (which meets the $\ge$ 5 cm threshold).
   • The sources define a High Tumor Burden patient as anyone with any lymph node $\ge$ 10 cm OR an ALC $\ge$ 25 x 10⁹/L AND any lymph node $\ge$ 5 cm. Because FJ meets both the ALC and nodal size criteria for this definition, he is classified as High Burden.

2. Monitoring for High Tumor Burden:

   • Weeks 1 and 2 (20 mg and 50 mg doses): For patients in the High Burden category, the prescribing information requires inpatient monitoring for the first dose of 20 mg and the first dose of 50 mg.
   • Inpatient Schedule: During these hospitalizations, blood chemistries (including potassium, uric acid, phosphorus, calcium, and creatinine) must be evaluated pre-dose and at 4, 8, 12, and 24 hours post-dose.
   • Subsequent Ramp-up Doses (100 mg, 200 mg, and 400 mg): Monitoring for these doses shifts to the outpatient setting. The required outpatient schedule for each of these subsequent first-time doses is pre-dose, 6-8 hours, and 24 hours after the dose.

The Role of Renal Function

FJ's creatinine clearance is 60 ml/min. While a CrCl < 80 ml/min is a factor that would require a "Medium Burden" patient to be considered for hospitalization, FJ already meets the criteria for mandatory inpatient monitoring due to his High Burden status based on ALC and nodal size.

[/expand]

Which of the following is used in first-line treatment of ITP (Immune Thrombocytopenic Purpura)?  

• A. Corticosteroids  
• B. Cyclosporine  
• C. IVIG  
• D. Rituximab  

[expand] The medication used in the first-line treatment of Immune Thrombocytopenic Purpura (ITP) is A. Corticosteroids.

Rationale: According to clinical guidelines provided for managing autoimmune complications in CLL:

• Initial Management: The sources explicitly state that the management of ITP typically begins with corticosteroids.
• Refractory Cases: Other treatments, such as IVIG (Option C), cyclosporine (Option B), and rituximab (Option D), are generally reserved for refractory cases (cases that do not respond to initial therapy).
• Additional Options: Synthetic thrombopoietin-like agents (e.g., romiplostim, eltrombopag, and avatrombopag) and fostamatinib are also listed as viable therapeutic options, often for cases where initial treatments fail.

[/expand]